Frankfurt - Delayed Quote EUR

Integrated Diagnostics Holdings plc (8I8.F)

Compare
0.3960 -0.0100 (-2.46%)
At close: 9:18:37 AM GMT+1
Loading Chart for 8I8.F
DELL
  • Previous Close 0.4060
  • Open 0.3840
  • Bid 0.4140 x --
  • Ask 0.4940 x --
  • Day's Range 0.3840 - 0.3960
  • 52 Week Range 0.2240 - 0.4560
  • Volume 0
  • Avg. Volume 0
  • Market Cap (intraday) 254.029M
  • Beta (5Y Monthly) 0.45
  • PE Ratio (TTM) 13.20
  • EPS (TTM) 0.0300
  • Earnings Date Mar 26, 2025 - Mar 31, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 16, 2022
  • 1y Target Est --

Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 3,000 diagnostic pathology tests, such as immunology, microbiology, haematology, endocrinology, clinical chemistry, molecular biology, parasitology, histopathology, and genetics. The company also provides radiology services, including positron emission tomography – computed tomography (PET-CT), magnetic resonance imaging (MRI), computed tomography (CT), mammography, ultrasound, x-ray, electromyography (EMG), electroencephalography, electroencephalogram (EEG), and electrocardiogram (ECG), as well as operates cath lab facilities. It operates in Egypt, Sudan, Jordan, Nigeria, and the Kingdom of Saudi Arabia. The company was founded in 1979 and is headquartered in Saint Helier, Jersey.

www.idhcorp.com

6,692

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 8I8.F

View More

Performance Overview: 8I8.F

Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

8I8.F
4.76%
FTSE 100
1.53%

1-Year Return

8I8.F
37.50%
FTSE 100
7.23%

3-Year Return

8I8.F
58.65%
FTSE 100
10.67%

5-Year Return

8I8.F
54.33%
FTSE 100
8.84%

Compare To: 8I8.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 8I8.F

View More

Valuation Measures

As of 1/6/2025
  • Market Cap

    248.23M

  • Enterprise Value

    247.83M

  • Trailing P/E

    15.62

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.68

  • Price/Book (mrq)

    4.43

  • Enterprise Value/Revenue

    2.73

  • Enterprise Value/EBITDA

    7.61

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.21%

  • Return on Assets (ttm)

    9.69%

  • Return on Equity (ttm)

    23.03%

  • Revenue (ttm)

    4.75B

  • Net Income Avi to Common (ttm)

    817.28M

  • Diluted EPS (ttm)

    0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.29B

  • Total Debt/Equity (mrq)

    35.86%

  • Levered Free Cash Flow (ttm)

    591.04M

Research Analysis: 8I8.F

View More